Kyowa Kirin Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Kyowa Kirin şirketinin toplam hissedar öz sermayesi ¥835.2B ve toplam borcu ¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥1,042.0B ve ¥206.7B dir. Kyowa Kirin 'in FAVÖK'ü ¥108.1B faiz karşılama oranı 48.1 dur. Şirketin ¥302.4B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

JP¥0

Borç

Faiz karşılama oranı	48.1x
Nakit	JP¥302.38b
Eşitlik	JP¥835.25b
Toplam yükümlülükler	JP¥206.72b
Toplam varlıklar	JP¥1.04t

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: KYKO.F 'nin kısa vadeli varlıkları ( ¥548.7B ) kısa vadeli yükümlülüklerini ( ¥155.7B ) aşıyor.

Uzun Vadeli Yükümlülükler: KYKO.F şirketinin kısa vadeli varlıkları ( ¥548.7B ) uzun vadeli yükümlülüklerini ( ¥51.0B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: KYKO.F borçsuzdur.

Borcun Azaltılması: KYKO.F un 5 yıl önce borcu yoktu.

Borç Kapsamı: KYKO.F un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: KYKO.F şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Kyowa Kirin Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

Kyowa Kirin Co., Ltd. Updates Earnings Guidance for He Fiscal Year 2024

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2024 Results on Feb 06, 2025

Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024

Kyowa Kirin Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2023, Payable on March 25, 2024; Provides Dividend Guidance for the Second Quarter of 2024

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 22, 2024

Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2023 Results on Feb 07, 2024

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

Kyowa Kirin Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

Kyowa Kirin Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2023

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2023

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2022, Payable on March 27, 2023; Provides Dividend Guidance for the Second Quarter of 2023

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2022 Results on Feb 07, 2023

Kyowa Kirin Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2022

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2022

Kyowa Kirin Co., Ltd. Receives European Commission Approval for Use of CRYSVITA(R) (burosumab) for the Treatment of Tumour-Induced Osteomalacia

Kyowa Kirin Co., Ltd. Announces Second Quarter End Dividend for the Fiscal Year Ending December 31, 2022, Payable from September 1, 2022; Provided Year End Dividend Guidance for the Fiscal Year Ending December 31, 2022

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending December 31, 2022

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 25, 2022

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

Kyowa Kirin Co., Ltd. Announces Publication of New Data Highlighting the Sustained Benefits of Treatment with CRYSVITA® (burosumab) in Adults with X-Linked Hypophosphataemia

Kyowa Kirin Initiates Phase 2 Clinical Study of G-Lasta® for the Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Blood Stem Cell Transplantation in Japan

Kyowa Kirin Co., Ltd. to Present Atopic Dermatitis Clinical Data from Khk4083/Amg 451 Phase 2 Study At the European Academy of Dermatology and Venereology 30Th Congress

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce First Patient Dosed in the Phase 3 Coastal Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-Cell Lymphoma

Kyowa Kirin Co., Ltd. Announces EU Approval for the Self-administration of CRYSVITA® (burosumab) to Treat X-Linked Hypophosphataemia (XLH)

MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program

MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib

MEI Pharma, Inc. and Kyowa Kirin Announce New Clinical Data on Zandelisib At American Society of Clinical Oncology Annual Meeting 2021

MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress

Kyowa Kirin Co., Ltd. Receives Positive CHMP Opinion for the Self-Administration of CRYSVITA® (burosumab) to Treat X-Linked Hypophosphataemia, a Rare Metabolic Bone Disorder

Kyowa Kirin Co., Ltd. to Report Q1, 2021 Results on May 06, 2021

Harvard University and Kyowa Kirin Co., Ltd. Enter into Strategic Research Alliance

Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2021

InveniAI LLC and Kyowa Kirin Co., Ltd. Enter AI-Powered Novel Target Discovery Collaboration

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2020 Results on Feb 04, 2021

Kyowa Kirin Announces European Commission (Ec) Approval of CRYSVITA® (Burosumab) for the Treatment of X-Linked Hypophosphataemia (XLH) in Older Adolescents and Adults

Kyowa Kirin Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin